Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Ocular mucous membrane pemphigoid (MMP) is an autoimmune, scarring conjunctivitis that can
lead to vision loss and permanent disability. It is a rare disorder with an estimated
incidence of 1 in 60,000. There are currently no FDA-approved medications for the treatment
of mucous membrane pemphigoid, highlighting a clear unmet need.
At present, moderate to severe disease requires off-label use of potent immunosuppressive
agents, such as oral anti-proliferatives (methotrexate, azathioprine, and mycophenolate),
rituximab (RTX) or cyclophosphamide (CyC). Recently, Janus kinase (JAK) inhibition with
baricitinib or tofacitinib been reported to be successful in one case of ocular MMP.
This is a randomized, single-masked, two-arm study of baricitinib vs anti-proliferatives for
ocular MMP.